Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Viking Therapeutics Inc VKTX

Healthcare Biotechnology
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non... see more

Recent & Breaking News (NDAQ:VKTX)

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

PR Newswire November 25, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

PR Newswire November 19, 2025

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

PR Newswire November 6, 2025

Viking Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire November 4, 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

PR Newswire October 29, 2025

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire October 22, 2025

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

PR Newswire October 21, 2025

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

PR Newswire October 15, 2025

Viking Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire August 28, 2025

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire August 19, 2025

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire July 23, 2025

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

PR Newswire July 16, 2025

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

PR Newswire June 25, 2025

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire April 23, 2025

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

PR Newswire April 16, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire March 26, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

PR Newswire March 11, 2025

Viking Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire March 4, 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

PR Newswire February 5, 2025

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

PR Newswire January 29, 2025